| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Immunome, Inc. (IMNM) has 13 insiders with recent SEC Form 4 filings, including 9 buys and 2 sells. IMNM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.04M | $45.83M | - | |
| CEO | 690.7K | $15.50M | - | |
| Dir | 341.1K | $7.66M | - | |
| Other | 242.0K | $5.43M | - | |
| CFO | 207.0K | $4.65M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | Bienaime Jean Jacques68 | Director | Buy | 7,800 | $7.78 | $60,684.00 | +33.0% | +25.8% | +192.1% | |
| Mar 24, 2025 | Bienaime Jean Jacques68 | Director | Buy | 7,000 | $8.21 | $57,470.00 | +42.1% | +7.2% | +148.0% | |
| Mar 24, 2025 | Tsai Philip76 | Chief Technology Officer | Buy | 12,300 | $8.42 | $103,566.00 | +58.6% | +7.2% | +148.0% | |
| Jan 31, 2025 | Siegall Clay B78 | President And CEO | Buy | 150,000 | $7.75 | $1,162,500.00 | +28.9% | -19.7% | +123.2% | |
| Nov 22, 2024 | Siegall Clay B78 | President And CEO | Buy | 100,000 | $9.62 | $962,181.46 | +11.0% | +3.0% | +88.7% | |
| Nov 21, 2024 | Lechleider Robert | Chief Medical Officer | Buy | 15,805 | $9.48 | $149,799.79 | New | +5.1% | +96.7% | |
| Nov 21, 2024 | Tsai Philip76 | Chief Technology Officer | Buy | 21,000 | $9.43 | $198,030.00 | New | +5.1% | +96.7% | |
| Sep 19, 2024 | Rosett Max | Chief Financial Officer | Sale+OE | 14,380 | $16.01 | $230,223.80 | -23.2% | -27.3% | -38.6% | |
| Aug 16, 2024 | Bienaime Jean Jacques68 | Director | Buy | 7,000 | $13.94 | $97,608.00 | +72.8% | -17.7% | -24.0% | |
| Aug 15, 2024 | Higgins Jack | Chief Scientific Officer | Sale+OE | 3,524 | $13.93 | $49,071.70 | -18.0% | -16.9% | -26.3% |